Table 1.
Baseline characteristics of study population according to BMI.
| Characteristics | Total (n = 970) | Tertile of BMI | P-value | ||
|---|---|---|---|---|---|
| Tertile 1 (<22.2 kg/m2) (n = 317) | Tertile 2 (22.2–24.4 kg/m2) (n = 312) | Tertile 3 (>24.4 kg/m2) (n = 341) | |||
| Age at implantation, years | 60.3 ± 13.5 | 60.4 ± 14.6 | 60.3 ± 12.6 | 60.3 ± 13.4 | 0.988 |
| Male | 707 (72.9%) | 198 (62.5%) | 241 (77.2%) | 268 (78.6%) | <0.001 |
| SBP, mmHg | 124.5 ± 17.4 | 124.0 ± 17.8 | 123.0 ± 16.5 | 126.4 ± 17.7 | 0.151 |
| DBP, mmHg | 76.9 ± 10.9 | 75.6 ± 11.3 | 76.5 ± 9.9 | 78.4 ± 11.2 | 0.002 |
| Primary prevention | 576 (59.4%) | 187 (59.0%) | 188 (60.3%) | 201 (58.9%) | 0.930 |
| NYHA, class III/IV | 484 (49.9%) | 172 (54.3%) | 146 (46.8%) | 166 (48.7%) | 0.148 |
| CRT-D | 266 (27.4%) | 89 (28.1%) | 91 (29.2%) | 86 (25.2%) | 0.503 |
| Ischemic cardiomyopathy | 324 (33.4%) | 96 (30.3%) | 98 (31.4%) | 130 (38.1%) | 0.069 |
| Dilated cardiomyopathy | 238 (24.5%) | 83 (26.2%) | 73 (23.4%) | 82 (24.0%) | 0.695 |
| Hypertrophic cardiomyopathy | 37 (3.8%) | 9 (2.8%) | 12 (3.8%) | 16 (4.7%) | 0.463 |
| Long QT syndrome | 12 (1.2%) | 5 (1.6%) | 3 (1.0%) | 4 (1.2%) | 0.777 |
| Hypertension | 305 (31.4%) | 89 (28.1%) | 92 (29.5%) | 124 (36.4%) | 0.049 |
| Diabetes mellitus | 101 (10.4%) | 24 (7.6%) | 34 (10.9%) | 43 (12.6%) | 0.101 |
| Stroke | 18 (1.9%) | 3 (1.0%) | 4 (1.3%) | 11 (3.2%) | 0.076 |
| Atrial fibrillation | 104 (10.7%) | 38 (12.0%) | 33 (10.6%) | 33 (9.7%) | 0.629 |
| Pre-implant syncope | 194 (20.0%) | 67 (21.1%) | 60 (19.2%) | 67 (19.7%) | 0.820 |
| LVEF, % | 42.5 ± 14.9 | 41.6 ± 15.0 | 42.9 ± 15.0 | 42.8 ± 14.8 | 0.476 |
| LVEDD, mm | 58.8 ± 13.1 | 58.1 ± 12.8 | 58.8 ± 13.5 | 59.6 ± 13.0 | 0.301 |
| β-Blocker | 566 (58.4%) | 177 (55.8%) | 181 (58.0%) | 208 (61.0%) | 0.402 |
| Amiodarone | 290 (29.9%) | 91 (28.7%) | 104 (33.3%) | 95 (27.9%) | 0.266 |
| ACEI or ARB | 360 (37.1%) | 128 (40.4%) | 100 (32.1%) | 132 (38.7%) | 0.073 |
| Loop diuretic | 280 (28.9%) | 84 (26.5%) | 93 (29.8%) | 103 (30.2%) | 0.523 |
| Aldosterone antagonists | 363 (37.4%) | 125 (39.4%) | 105 (33.7%) | 133 (39.0%) | 0.246 |
Continuous data and categorical data were given as mean ± SD and number (percentage), respectively.
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; CRT-D, cardiac resynchronization therapy defibrillator; DBP, diastolic blood pressure; LVEF, left ventricular ejection fraction; LVEDD, left ventricular end-systolic dimension; NYHA, New York Heart Association; SBP, systolic blood pressure.